Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a hormone shot help comatose cardiac arrest survivors wake up?

NCT ID NCT00999583

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether high doses of epoetin alpha, a drug that boosts red blood cells and may protect the brain, could improve recovery in 500 comatose adults who survived a cardiac arrest. Half received the drug plus standard care, half got standard care alone. The main goal was to see if more patients reached the best level of brain function by day 60.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
epoetin alpha (a lab-made version of erythropoietin, a hormone that boosts red blood cells and may protect the brain)
What this could lead to
If it works, this could point toward a treatment that helps more people wake up with good brain function after a cardiac arrest.
What could go wrong
This trial is already completed, so results are known. The drug may not improve outcomes and could raise the risk of blood clots. The study is also limited to a specific type of cardiac arrest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

500 people

The number who actually took part.

Start date

Oct 2009

Finished

May 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age between 18 and 80 * Witnessed out-of-hospital cardiac arrest, presumed of cardiac origin (non asphyxic) * Time from cardiac arrest and recovery of circulatory activity less than 60 minutes * Persistent coma after ROSC (Coma Glasgow Scale \< 7) Exclusion criteria: * Out-of-hospital cardiac arrest with evidence of extra-cardiac cause (trauma, sepsis, acute respiratory insufficiency, asphyxia) * Previous or chronic treatment with erythropoietin or analogues * Pregnancy * Rapidly fatal underlying disease (expected life duration \< 6 months) * No social security

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Comatose survivors of cardiac arrest are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical intensive care unit of Cochin-St Vincent de Paul university Hospital

    Paris, 75679, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.